ESC 2026 Guidelines on Cardiovascular Disease Prevention formally recommend GLP-1 receptor agonists for CV risk reduction independent of glycaemic control

The European Society of Cardiology 2026 CVD Prevention Guidelines ↗ upgraded the recommendation for GLP-1 receptor agonists (GLP-1 RAs) to Class I, Level of Evidence A for reducing MACE in patients with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥27 kg/m² — explicitly independent of diabetes status. Previously, a Class IIa recommendation existed for patients with T2DM + CVD. The Class I designation for non-diabetic patients is new and reflects accumulated RCT evidence including SELECT (semaglutide 2.4 mg, NEJM 2023) ↗ — a 20% reduction in MACE in overweight/obese non-diabetic patients with prior CVD.

GLP-1 RAs activate the glucagon-like peptide-1 receptor (GLP-1R), which is expressed in the pancreas, heart, kidneys, brain, and blood vessels. Cardiometabolic effects beyond glucose-lowering include: reduced inflammatory signalling in atherosclerotic plaques (GLP-1R on macrophages), improved endothelial function, reduced blood pressure (~2–4 mmHg systolic), and weight loss (5–15% from baseline depending on agent and dose). The cardiovascular benefits appear partially independent of weight reduction — the mechanism is debated but likely involves direct anti-inflammatory and anti-atherogenic effects. Current approved agents: semaglutide (Ozempic/Wegovy — weekly SC), liraglutide (Victoza/Saxenda — daily SC), dulaglutide (Trulicity — weekly SC), and oral semaglutide (Rybelsus). See our Ozempic CV label update.

Class I evidence rests on four major RCTs: LEADER (liraglutide, NEJM 2016) ↗: 13% RRR in MACE, patients with T2DM + CVD; SUSTAIN-6 (semaglutide 0.5/1 mg SC, NEJM 2018) ↗: 26% RRR in MACE, T2DM + high CV risk; STEP-HFpEF (semaglutide 2.4 mg in HFpEF + obesity) ↗; SELECT (semaglutide 2.4 mg, non-diabetic): 20% RRR in MACE. The ESC now positions GLP-1 RAs alongside statins and ACE inhibitors as foundational CV risk-reduction therapy in ASCVD patients with overweight/obesity. See our blood pressure medications guide for the cardiometabolic drug landscape.

The Class I ESC recommendation is expected to drive formulary updates across European health systems and influence EMA label extensions for CV indications. In Australia, semaglutide 2.4 mg (Wegovy) has received PBS listing for weight management — see our Wegovy heart failure label update. Clinicians should be aware of GLP-1 RA adverse effects: nausea/vomiting (most common — dose-related), rare pancreatitis (see our pancreatitis review), medullary thyroid carcinoma risk (contraindicated with MEN2/familial MTC), and injection site reactions. Cost-effectiveness in non-diabetic CVD populations remains under active HTA review across multiple jurisdictions.